Investigating how variations in CD3z ITAM affect CAR T cell performance
The Role of CD3z ITAM (Immunoreceptor Tyrosine-Based Activation Motif) diversity in CAR T cell Force and Function
This study is looking at ways to make CAR T cell therapy better for people with certain blood cancers by exploring how different parts of the immune cells can help them work longer and more effectively, which could lead to fewer side effects and better results for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project ID | NIH-10981241 on NIH RePORTER |
What this research studies
This research focuses on improving CAR T cell therapy by examining the role of CD3z ITAM diversity in enhancing the effectiveness and longevity of these engineered immune cells. By analyzing how different ITAM sequences influence T cell activation and function, the study aims to optimize CAR constructs to reduce side effects and improve patient outcomes. The approach involves detailed assessments of T cell signaling and interactions in a controlled laboratory setting, which may lead to more effective treatments for certain blood cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with B cell malignancies who are considering or currently undergoing CAR T cell therapy.
Not a fit: Patients with solid tumors or those who do not have B cell malignancies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective CAR T cell therapies for patients with B cell malignancies.
How similar studies have performed: Previous research has shown promising results in optimizing CAR T cell therapies, indicating that this approach has potential for success.
Where this research is happening
Salt Lake City, United States
- University of Utah — Salt Lake City, United States (Active)
Researchers
- Principal investigator: Bettini, Matthew — University of Utah
- Study coordinator: Bettini, Matthew
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.